ArticleBMC gastroenterology2026
Mapping the evolution of inflammatory bowel disease care in Brazil: a comparison of cross-sectional surveys from 2017 and 2023.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Brazil, the epidemiology and care pathways of patients with inflammatory bowel disease (IBD) are poorly documented. Mapping the patient journey is key to identifying gaps and informing health policies. This study explores the Second Journey of IBD patients in Brazil and compares the findings with those from the First Journey.
methodsTwo cross-sectional online surveys were conducted in 2017 and 2023 with adults diagnosed with IBD. The questionnaire addressed challenges in diagnosis, treatment, and disease impacts. Comparisons between survey waves were performed using logistic regression models adjusted for sex, age, and region, with results presented as adjusted absolute differences in prevalence and 95% confidence intervals.
resultsIn the Second Journey (n = 2634), most participants were women (72.9%), aged 35-54 years (50.8%), and Crohn's disease was the most common diagnosis (58.7%). Compared to the First Journey (n = 3549), a lower proportion of patients were diagnosed within one year of symptom onset (58.8% vs. 53.8%), corresponding to an adjusted difference of -3.5% percentage points (p.p.) (95% CI -6.1; -1.0). The proportion of patients using biological therapies was higher (40.6% vs. 60.9%), as was attendance at multidisciplinary clinics (8.0% vs. 10.0%). A higher proportion of patients reported being satisfied with treatment (30.2% vs. 41.6%; +10.4 p.p., 95% CI 8.0; 12.9). Fatigue was the most frequent symptom, even during remission.
conclusionsThe Second Journey highlights the persistent impact of IBD on daily life. Gaps in multidisciplinary care and patient experience remain, emphasizing the need for more comprehensive care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.